



29 April 2020

ASX ANNOUNCEMENT

CHANGE IN EXERCISE PRICE OF OPTIONS

Brisbane, Australia and Carlsbad, Calif. – ImpediMed Limited (ASX: IPD) (**ImpediMed** or the **Company**) announced a non-renounceable accelerated entitlement offer of 13 new shares (**New Shares**) for every 10 shares at a price of \$0.0375 per New Share on 2 April 2020 (**Entitlement Offer**).

ImpediMed advises that, as a consequence of the Entitlement Offer, the exercise prices of various unquoted options over fully paid ordinary shares in the capital of ImpediMed (**Options**) are to be recalculated based on the formula set out in the rules of the Company's 2014 Employee Incentive Plan adopted by a resolution of directors on 18 September 2014 (**EIP**).

The revised exercise prices of the EIP Options will change on 6 May 2020 and are set out in the table below.

Options (#)	Current exercise price (A\$)	New exercise price (A\$)
195,000	0.0400	0.0354
450,000	0.1100	0.1054
498,000	0.1333	0.1286
8,001,362	0.1500	0.1454
230,000	0.1700	0.1654
70,000	0.2283	0.2236
100,000	0.2300	0.2254
578,000	0.5183	0.5136
53,500	0.6383	0.6336
306,000	0.6783	0.6736
4,234,000	0.6883	0.6836
120,000	0.7383	0.7336
4,974,000	0.8133	0.8086
672,000	0.8683	0.8636
375,000	0.9283	0.9236

Options (#)	Current exercise price (A\$)	New exercise price (A\$)
512,500	0.9983	0.9936
200,000	1.0283	1.0236
50,000	1.0483	1.0436
200,000	1.3183	1.3136
1,207,000	1.4583	1.4536
566,500	1.4683	1.4636
518,000	1.6583	1.6536

Authorised for release by the Board of Directors of ImpediMed Limited.

Contact Details

Investor Relations Contact:

Mike Bassett, ImpediMed

T: +61 407 431 432

E: mbassett@impedimed.com

Media Contact:

Kyahn Williamson, WE Buchan

T: +61 3 9866 4722

E: kwilliamson@buchanwe.com.au

About ImpediMed

Founded and headquartered in Brisbane, Australia with US and European operations, ImpediMed is a medical software technology company that non-invasively measures, monitors and manages fluid status and tissue composition using bioimpedance spectroscopy.

ImpediMed produces a family of FDA cleared and CE Marked medical devices, including SOZO® for multiple indications including heart failure, protein calorie malnutrition and lymphoedema, sold in select markets globally.

For more information, visit www.impedimed.com.